Hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and mitomycin-C (± granulocyte-colony stimulating factor) in the treatment of patients with locally advanced head and neck carcinoma

Cancer

Volumn 80, Issue 2, 1997, Pages 266-276

  Abitbol, André A ^a,b   Sridhar, Kasi S ^c   Lewin, Alan A ^a,b   Schwade, James G ^a,d   Raub Jr , William ^a   Wolfson, Aaron ^a   Gonzalez Angulo, Carlos ^a   Adessa, Anthony ^a   Goodwin, W Jarrard ^a   Markoe, Arnold M ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b BAPTIST HOSPITAL OF MIAMI   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d Quality Oncology L C   (United States)

Author keywords

Combination chemotherapy; Concurrent chemotherapy and radiation therapy; Head and neck carcinoma; Hyperfractionated radiation therapy

Indexed keywords

CISPLATIN; FLUOROURACIL; MITOMYCIN C; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; ASPIRATION PNEUMONIA; BLOOD TOXICITY; CLINICAL TRIAL; DERMATITIS; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, HIGH-ENERGY; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS;

EID: 0030959666     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970715)80:2<266::AID-CNCR15>3.0.CO;2-S     Document Type: Article

References (38)

1. Withers HR. Biologic basis for altered fractionation schemes. Cancer 1985;55(Suppl):2086.
2. Van den Bogaert W, Horiot J-C, van der Schueren E. Radiotherapy with multiple fractions per day. In Steel GG, Adams GE, Horwich A, editors. The biologic basis of radiotherapy. 2nd edition. New York: Elsevier Science Publishers, 1989: 209.
3. Fowler JF. Brief summary of radiobiological principles in fractionated radiotherapy. Semin Radiat Oncol 1992;2:16.
4. Schwade JG, Markoe AM, Abitbol AA, et al. Accelerating hyperfractionation for carcinoma of the head and neck. Semin Radiat Oncol 1992;2:51.
5. Peters LJ, Ang KK, Thames HD Jr. Accelerated fractionation in the radiation treatment of head and neck cancer: a critical comparison of different strategies. Acta Oncol 1988;27(Fasc. 2):185.
6. Fu KK. Integration of chemotherapy and radiotherapy for organ preservation in head and neck cancer. In: Johnson JT, Dikol Kar MS, editors. Head and neck cancer. Volume III. New York: Elsevier Science Publishers, 1993:17.
7. Yokes EE, Weichselbaum RR. Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol 1990;8:911.
8. Horiot JC, LeFur R, N' Guyen T, Chenal C, Schraub S, Alfonsi S, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992;25:231.
9. Pinto LH, Canary PC, Araújo CM, Bacelar SC, Souhami L. Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stage III and IV oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1991;21:557.
10. Sanchìz F, Milla A, Torner L, Bonet F, Artola N, Carren̂o L, et al. Single fraction per day versus two fractions versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 1990;19:1347.
11. Cox JD, Pajak TF, Marcial VA, Hanks GE, Mohiuddin M, Fu KK, et al. Dose response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: preliminary results of Radiation Therapy Oncology Group Protocol 83-13. Int J Radiat Oncol Biol Phys 1990;18:515.
12. Sartorelli AC. Therapeutic attack of hypoxic cells of solid tumors. Cancer Res 1988;48:775.
13. Looney WB, Shaffner JG, Trefil JG, et al. Solid tumor models for the assessment of different treatment modalities. IV. The combined effect of radiation and 5-fluorouracil. Br J Cancer 1976;34:254.
14. Coughlin CT, Richmond RC. Biologic and clinical developments of cisplatin combined with radiation: concepts, utility, projections for new trials, and the emergence of carboplatin. Semin Oncol 1989;16(Suppl. 6):31.
15. Byfield JE. Useful interactions between 5-fluorouracil and radiation in man: 5-fluorouracil as a radiosensitizer. In: Hill BT, Bellamy AS, editors. Antitumor drug-radiation interactions. Boca Raton: CRC Press, 1990:87.
16. Douple EB. Keynote address: Platinum-radiation interactions. Monogr Natl Cancer Inst 1988;6:315.
17. Rockwell S. Cytotoxicities of mitomycin-C and x-rays to aerobic and hypoxic cells in vitro. Int J Radiat Oncol Biol Phys 1982;8:31-5.
18. Abitbol AA, Schwade JG, Lewin AA, Sridhar K, Brandon AH, Markoe AM, et al. Hyperfractionated radiation therapy and concurrent 5-fluorouracil, cisplatin and mitomycin c in head and neck carcinoma. Am J Clin Oncol 1992;15:250.
19. Neta R, Oppenheim JJ. Radioprotection with cytokines: Learning from nature to cope with radiation damage. Cancer Cells 1991;3(10):391.
20. Beahrs OH, Henson DE, Hulter RVP, Kennedy BJ, editors. American Joint Committee on Cancer Manual for Staging of Cancer. 3rd edition. Philadelphia: J.B. Lippincott Co., 1989.
21. Fu KK, Phillips TL, Silverberg IJ, Jacobs C, Goffinet DR, Chun C, et al. Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group Randomized Trial. J Clin Oncol 1987;5:1410.
22. Bentzen SM, Ruifrok AC, Thames HD. Repair capacity and kinetics for human mucosa and epithelial tumors in the head and neck: clinical data on the effect of changing the time interval between multiple fractions per day in radiotherapy. Radiother Oncol 1996;38:89.
23. Cox JD, Pajak TF, Marcial VA, Coia L, Mohiuddin M, Fu KK, et al. Interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: results from Radiation Therapy Oncology Group protocol 83-13. Int J Radiat Oncol Biol Phys 1991;20:1191.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:447.
25. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163.
26. Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley & Sons, Inc., 1981.
27. Cox DR: Regression models and lifetables. J R Stat Soc B 1972;34:187.10.
28. Garden AS, Morrison WH, Ang KK, Peters LJ. Hyperfractionated radiation in the treatment of squamous cell carcinomas of the head and neck: a comparison of two fractionation schedules. Int J Radiat Oncol Biol Phys 1995;31:493.
29. Ang KK, Peters, LJ. Altered fractionation in radiation oncology. In: De Vita VT, Jr., Hellman S, Rosenberg SA, editors. Principles and practice of oncology. Philadelphia: J.B. Lippincott Co., PPO updates, 1994;8(No. 4, 1.).
30. Pedersen-Bjergaard J, Larsen PP, Andersson M, Daugaard G, Ersboll J, Hansen SW. Therapy-related myolodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant disease in the Copenhagen series. Leukemia 1993;7(12):1975-86.
31. Fowler JF, Lindstrom MJ. Loss of control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 1992;23:457.
32. Cox JD, Pajak TF, Marcial VA, Coia L, Mohiuddin M, Fu KK, et al. Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: new evidence of accelerated proliferation from Radiation Therapy Oncology Group Protocol 83-13. Cancer 1992;69:2744.
33. Wong WW, Mick R, Haraf DJ, Weichselbaum RR, Vokes EE. Time-dose relationship for local tumor control following alternate week concomitant radiation and chemotherapy of advanced head and neck cancer. Int J Radiat Oncol Biol Phys 1994;29(1):153.
34. Keane TJ, Cummings BJ, O'Sullivan B, Payne D, Rawlinson E, MacKenzie R, et al. A randomized trial of radiation therapy compared to split course radiation therapy combined with mitomycin C and 5 fluorouracil as initial treatment for advanced laryngeal and hypopharyngeal squamous carcinoma. Int J Radiat Oncol Biol Phys 1993;25:613.
35. Weissberg JB, Son YH, Papac RJ, Sasaki C, Fischer DB, Lawrence R, et al. Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. Int J Radiat Oncol Biol Phys 1989;17:3.
36. Vokes EE, Haraf DJ, Mick R, McEvilly J-M, Weichselbaum RR. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer. J Clin Oncol 1994;12:2351-9.
37. Steren A, Sevin B-U, Perras J, Ramos R, Angioli R, Nguyen H, et al. Taxol as a radiosensitizer: a flow cytometric study. Gynecol Oncol 1993;50:89-93.
38. Coleman CN, Bump EA, Kramer RA. Chemical modifiers of cancer treatment. J Clin Oncol 1988;6(A):709-33.